The global Hospital Acquired Pneumonia Drugs market was valued at US$ 2807.5 million in 2023 and is anticipated to reach US$ 3218.1 million by 2030, witnessing a CAGR of 1.5% during the forecast period 2024-2030.

Hospital Acquired Pneumonia Drugs Market

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

This report aims to provide a comprehensive presentation of the global market for Hospital Acquired Pneumonia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital Acquired Pneumonia Drugs.

Report Scope

The Hospital Acquired Pneumonia Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital Acquired Pneumonia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hospital Acquired Pneumonia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hospital Acquired Pneumonia Drugs Market Report

Report Metric	Details
Report Name	Hospital Acquired Pneumonia Drugs Market
Accounted market size in 2023	US$ 2807.5 million
Forecasted market size in 2030	US$ 3218.1 million
CAGR	1.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Phase II Early Phase (Phase I & II)
Segment by Application	Hospital Pharmacies Retail Pharmacies Drug Store E-Commerce
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Basilea Pharmaceutica, Meiji Holdings, Cubist Pharmaceutical, Aridis Pharmaceutical, Valneva, Bayer, GlaxoSmithKline, Merck, Achaogen, AstraZeneca
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hospital Acquired Pneumonia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hospital Acquired Pneumonia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Hospital Acquired Pneumonia Drugs Market growing?

Ans: The Hospital Acquired Pneumonia Drugs Market witnessing a CAGR of 1.5% during the forecast period 2024-2030.

What is the Hospital Acquired Pneumonia Drugs Market size in 2030?

Ans: The Hospital Acquired Pneumonia Drugs Market size in 2030 will be US$ 3218.1 million.

Who are the main players in the Hospital Acquired Pneumonia Drugs Market report?

Ans: The main players in the Hospital Acquired Pneumonia Drugs Market are Basilea Pharmaceutica, Meiji Holdings, Cubist Pharmaceutical, Aridis Pharmaceutical, Valneva, Bayer, GlaxoSmithKline, Merck, Achaogen, AstraZeneca

What are the Application segmentation covered in the Hospital Acquired Pneumonia Drugs Market report?

Ans: The Applications covered in the Hospital Acquired Pneumonia Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Drug Store, E-Commerce

What are the Type segmentation covered in the Hospital Acquired Pneumonia Drugs Market report?

Ans: The Types covered in the Hospital Acquired Pneumonia Drugs Market report are Phase II, Early Phase (Phase I & II)

1 Hospital Acquired Pneumonia Drugs Market Overview

1.1 Product Overview and Scope of Hospital Acquired Pneumonia Drugs

1.2 Hospital Acquired Pneumonia Drugs Segment by Type

1.2.1 Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Phase II

1.2.3 Early Phase (Phase I & II)

1.3 Hospital Acquired Pneumonia Drugs Segment by Application

1.3.1 Global Hospital Acquired Pneumonia Drugs Market Value by Application: (2024-2030)

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Drug Store

1.3.5 E-Commerce

1.4 Global Hospital Acquired Pneumonia Drugs Market Size Estimates and Forecasts

1.4.1 Global Hospital Acquired Pneumonia Drugs Revenue 2019-2030

1.4.2 Global Hospital Acquired Pneumonia Drugs Sales 2019-2030

1.4.3 Global Hospital Acquired Pneumonia Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Hospital Acquired Pneumonia Drugs Market Competition by Manufacturers

2.1 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Hospital Acquired Pneumonia Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Hospital Acquired Pneumonia Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Product Type & Application

2.7 Hospital Acquired Pneumonia Drugs Market Competitive Situation and Trends

2.7.1 Hospital Acquired Pneumonia Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Hospital Acquired Pneumonia Drugs Players Market Share by Revenue

2.7.3 Global Hospital Acquired Pneumonia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Hospital Acquired Pneumonia Drugs Retrospective Market Scenario by Region

3.1 Global Hospital Acquired Pneumonia Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Hospital Acquired Pneumonia Drugs Global Hospital Acquired Pneumonia Drugs Sales by Region: 2019-2030

3.2.1 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2019-2024

3.2.2 Global Hospital Acquired Pneumonia Drugs Sales by Region: 2025-2030

3.3 Global Hospital Acquired Pneumonia Drugs Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2019-2030

3.3.1 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2019-2024

3.3.2 Global Hospital Acquired Pneumonia Drugs Revenue by Region: 2025-2030

3.4 North America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country

3.4.1 North America Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)

3.4.3 North America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country

3.5.1 Europe Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)

3.5.3 Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country

3.7.1 Latin America Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)

3.7.3 Latin America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Hospital Acquired Pneumonia Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Hospital Acquired Pneumonia Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2019-2030)

4.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Type (2019-2024)

4.1.2 Global Hospital Acquired Pneumonia Drugs Sales by Type (2025-2030)

4.1.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2019-2030)

4.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2019-2030)

4.2.1 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2019-2024)

4.2.2 Global Hospital Acquired Pneumonia Drugs Revenue by Type (2025-2030)

4.2.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Hospital Acquired Pneumonia Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2019-2030)

5.1.1 Global Hospital Acquired Pneumonia Drugs Sales by Application (2019-2024)

5.1.2 Global Hospital Acquired Pneumonia Drugs Sales by Application (2025-2030)

5.1.3 Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2019-2030)

5.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2019-2030)

5.2.1 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2019-2024)

5.2.2 Global Hospital Acquired Pneumonia Drugs Revenue by Application (2025-2030)

5.2.3 Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Hospital Acquired Pneumonia Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Basilea Pharmaceutica

6.1.1 Basilea Pharmaceutica Corporation Information

6.1.2 Basilea Pharmaceutica Description and Business Overview

6.1.3 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product Portfolio

6.1.5 Basilea Pharmaceutica Recent Developments/Updates

6.2 Meiji Holdings

6.2.1 Meiji Holdings Corporation Information

6.2.2 Meiji Holdings Description and Business Overview

6.2.3 Meiji Holdings Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Meiji Holdings Hospital Acquired Pneumonia Drugs Product Portfolio

6.2.5 Meiji Holdings Recent Developments/Updates

6.3 Cubist Pharmaceutical

6.3.1 Cubist Pharmaceutical Corporation Information

6.3.2 Cubist Pharmaceutical Description and Business Overview

6.3.3 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio

6.3.5 Cubist Pharmaceutical Recent Developments/Updates

6.4 Aridis Pharmaceutical

6.4.1 Aridis Pharmaceutical Corporation Information

6.4.2 Aridis Pharmaceutical Description and Business Overview

6.4.3 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product Portfolio

6.4.5 Aridis Pharmaceutical Recent Developments/Updates

6.5 Valneva

6.5.1 Valneva Corporation Information

6.5.2 Valneva Description and Business Overview

6.5.3 Valneva Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Valneva Hospital Acquired Pneumonia Drugs Product Portfolio

6.5.5 Valneva Recent Developments/Updates

6.6 Bayer

6.6.1 Bayer Corporation Information

6.6.2 Bayer Description and Business Overview

6.6.3 Bayer Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Bayer Hospital Acquired Pneumonia Drugs Product Portfolio

6.6.5 Bayer Recent Developments/Updates

6.7 GlaxoSmithKline

6.6.1 GlaxoSmithKline Corporation Information

6.6.2 GlaxoSmithKline Description and Business Overview

6.6.3 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product Portfolio

6.7.5 GlaxoSmithKline Recent Developments/Updates

6.8 Merck

6.8.1 Merck Corporation Information

6.8.2 Merck Description and Business Overview

6.8.3 Merck Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Merck Hospital Acquired Pneumonia Drugs Product Portfolio

6.8.5 Merck Recent Developments/Updates

6.9 Achaogen

6.9.1 Achaogen Corporation Information

6.9.2 Achaogen Description and Business Overview

6.9.3 Achaogen Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Achaogen Hospital Acquired Pneumonia Drugs Product Portfolio

6.9.5 Achaogen Recent Developments/Updates

6.10 AstraZeneca

6.10.1 AstraZeneca Corporation Information

6.10.2 AstraZeneca Description and Business Overview

6.10.3 AstraZeneca Hospital Acquired Pneumonia Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 AstraZeneca Hospital Acquired Pneumonia Drugs Product Portfolio

6.10.5 AstraZeneca Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hospital Acquired Pneumonia Drugs Industry Chain Analysis

7.2 Hospital Acquired Pneumonia Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hospital Acquired Pneumonia Drugs Production Mode & Process

7.4 Hospital Acquired Pneumonia Drugs Sales and Marketing

7.4.1 Hospital Acquired Pneumonia Drugs Sales Channels

7.4.2 Hospital Acquired Pneumonia Drugs Distributors

7.5 Hospital Acquired Pneumonia Drugs Customers

8 Hospital Acquired Pneumonia Drugs Market Dynamics

8.1 Hospital Acquired Pneumonia Drugs Industry Trends

8.2 Hospital Acquired Pneumonia Drugs Market Drivers

8.3 Hospital Acquired Pneumonia Drugs Market Challenges

8.4 Hospital Acquired Pneumonia Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Basilea Pharmaceutica

Meiji Holdings

Cubist Pharmaceutical

Aridis Pharmaceutical

List of Tables

Table 1. Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Hospital Acquired Pneumonia Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Hospital Acquired Pneumonia Drugs Sales (Kg) of Key Manufacturers (2019-2024)

Table 5. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Hospital Acquired Pneumonia Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Hospital Acquired Pneumonia Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Hospital Acquired Pneumonia Drugs Average Price (USD/Kg) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Hospital Acquired Pneumonia Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Hospital Acquired Pneumonia Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hospital Acquired Pneumonia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital Acquired Pneumonia Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hospital Acquired Pneumonia Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Hospital Acquired Pneumonia Drugs Sales by Region (2019-2024) & (Kg)

Table 18. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Hospital Acquired Pneumonia Drugs Sales by Region (2025-2030) & (Kg)

Table 20. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Hospital Acquired Pneumonia Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Hospital Acquired Pneumonia Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Hospital Acquired Pneumonia Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2024) & (Kg)

Table 27. North America Hospital Acquired Pneumonia Drugs Sales by Country (2025-2030) & (Kg)

Table 28. North America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Hospital Acquired Pneumonia Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Hospital Acquired Pneumonia Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Hospital Acquired Pneumonia Drugs Sales by Country (2019-2024) & (Kg)

Table 32. Europe Hospital Acquired Pneumonia Drugs Sales by Country (2025-2030) & (Kg)

Table 33. Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Hospital Acquired Pneumonia Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Region (2019-2024) & (Kg)

Table 37. Asia Pacific Hospital Acquired Pneumonia Drugs Sales by Region (2025-2030) & (Kg)

Table 38. Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Hospital Acquired Pneumonia Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Hospital Acquired Pneumonia Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Hospital Acquired Pneumonia Drugs Sales by Country (2019-2024) & (Kg)

Table 42. Latin America Hospital Acquired Pneumonia Drugs Sales by Country (2025-2030) & (Kg)

Table 43. Latin America Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Hospital Acquired Pneumonia Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Hospital Acquired Pneumonia Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Hospital Acquired Pneumonia Drugs Sales by Country (2019-2024) & (Kg)

Table 47. Middle East & Africa Hospital Acquired Pneumonia Drugs Sales by Country (2025-2030) & (Kg)

Table 48. Middle East & Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Hospital Acquired Pneumonia Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Hospital Acquired Pneumonia Drugs Sales (Kg) by Type (2019-2024)

Table 51. Global Hospital Acquired Pneumonia Drugs Sales (Kg) by Type (2025-2030)

Table 52. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Hospital Acquired Pneumonia Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Hospital Acquired Pneumonia Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Type (2019-2024)

Table 59. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Type (2025-2030)

Table 60. Global Hospital Acquired Pneumonia Drugs Sales (Kg) by Application (2019-2024)

Table 61. Global Hospital Acquired Pneumonia Drugs Sales (Kg) by Application (2025-2030)

Table 62. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Hospital Acquired Pneumonia Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Hospital Acquired Pneumonia Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Hospital Acquired Pneumonia Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Application (2019-2024)

Table 69. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Application (2025-2030)

Table 70. Basilea Pharmaceutica Corporation Information

Table 71. Basilea Pharmaceutica Description and Business Overview

Table 72. Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 73. Basilea Pharmaceutica Hospital Acquired Pneumonia Drugs Product

Table 74. Basilea Pharmaceutica Recent Developments/Updates

Table 75. Meiji Holdings Corporation Information

Table 76. Meiji Holdings Description and Business Overview

Table 77. Meiji Holdings Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 78. Meiji Holdings Hospital Acquired Pneumonia Drugs Product

Table 79. Meiji Holdings Recent Developments/Updates

Table 80. Cubist Pharmaceutical Corporation Information

Table 81. Cubist Pharmaceutical Description and Business Overview

Table 82. Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 83. Cubist Pharmaceutical Hospital Acquired Pneumonia Drugs Product

Table 84. Cubist Pharmaceutical Recent Developments/Updates

Table 85. Aridis Pharmaceutical Corporation Information

Table 86. Aridis Pharmaceutical Description and Business Overview

Table 87. Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 88. Aridis Pharmaceutical Hospital Acquired Pneumonia Drugs Product

Table 89. Aridis Pharmaceutical Recent Developments/Updates

Table 90. Valneva Corporation Information

Table 91. Valneva Description and Business Overview

Table 92. Valneva Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 93. Valneva Hospital Acquired Pneumonia Drugs Product

Table 94. Valneva Recent Developments/Updates

Table 95. Bayer Corporation Information

Table 96. Bayer Description and Business Overview

Table 97. Bayer Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 98. Bayer Hospital Acquired Pneumonia Drugs Product

Table 99. Bayer Recent Developments/Updates

Table 100. GlaxoSmithKline Corporation Information

Table 101. GlaxoSmithKline Description and Business Overview

Table 102. GlaxoSmithKline Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 103. GlaxoSmithKline Hospital Acquired Pneumonia Drugs Product

Table 104. GlaxoSmithKline Recent Developments/Updates

Table 105. Merck Corporation Information

Table 106. Merck Description and Business Overview

Table 107. Merck Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 108. Merck Hospital Acquired Pneumonia Drugs Product

Table 109. Merck Recent Developments/Updates

Table 110. Achaogen Corporation Information

Table 111. Achaogen Description and Business Overview

Table 112. Achaogen Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 113. Achaogen Hospital Acquired Pneumonia Drugs Product

Table 114. Achaogen Recent Developments/Updates

Table 115. AstraZeneca Corporation Information

Table 116. AstraZeneca Description and Business Overview

Table 117. AstraZeneca Hospital Acquired Pneumonia Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)

Table 118. AstraZeneca Hospital Acquired Pneumonia Drugs Product

Table 119. AstraZeneca Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Hospital Acquired Pneumonia Drugs Distributors List

Table 123. Hospital Acquired Pneumonia Drugs Customers List

Table 124. Hospital Acquired Pneumonia Drugs Market Trends

Table 125. Hospital Acquired Pneumonia Drugs Market Drivers

Table 126. Hospital Acquired Pneumonia Drugs Market Challenges

Table 127. Hospital Acquired Pneumonia Drugs Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Hospital Acquired Pneumonia Drugs

Figure 2. Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Hospital Acquired Pneumonia Drugs Market Share by Type in 2023 & 2030

Figure 4. Phase II Product Picture

Figure 5. Early Phase (Phase I & II) Product Picture

Figure 6. Global Hospital Acquired Pneumonia Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Hospital Acquired Pneumonia Drugs Market Share by Application in 2023 & 2030

Figure 8. Hospital Pharmacies

Figure 9. Retail Pharmacies

Figure 10. Drug Store

Figure 11. E-Commerce

Figure 12. Global Hospital Acquired Pneumonia Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 13. Global Hospital Acquired Pneumonia Drugs Market Size (2019-2030) & (US$ Million)

Figure 14. Global Hospital Acquired Pneumonia Drugs Sales (2019-2030) & (Kg)

Figure 15. Global Hospital Acquired Pneumonia Drugs Average Price (USD/Kg) & (2019-2030)

Figure 16. Hospital Acquired Pneumonia Drugs Report Years Considered

Figure 17. Hospital Acquired Pneumonia Drugs Sales Share by Manufacturers in 2023

Figure 18. Global Hospital Acquired Pneumonia Drugs Revenue Share by Manufacturers in 2023

Figure 19. The Global 5 and 10 Largest Hospital Acquired Pneumonia Drugs Players: Market Share by Revenue in 2023

Figure 20. Hospital Acquired Pneumonia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 21. Global Hospital Acquired Pneumonia Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 22. North America Hospital Acquired Pneumonia Drugs Sales Market Share by Country (2019-2030)

Figure 23. North America Hospital Acquired Pneumonia Drugs Revenue Market Share by Country (2019-2030)

Figure 24. U.S. Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 25. Canada Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Europe Hospital Acquired Pneumonia Drugs Sales Market Share by Country (2019-2030)

Figure 27. Europe Hospital Acquired Pneumonia Drugs Revenue Market Share by Country (2019-2030)

Figure 28. Germany Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. France Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. U.K. Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Italy Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Russia Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Hospital Acquired Pneumonia Drugs Sales Market Share by Region (2019-2030)

Figure 34. Asia Pacific Hospital Acquired Pneumonia Drugs Revenue Market Share by Region (2019-2030)

Figure 35. China Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Japan Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. South Korea Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. India Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Australia Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Taiwan Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Indonesia Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Thailand Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Malaysia Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Philippines Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Hospital Acquired Pneumonia Drugs Sales Market Share by Country (2019-2030)

Figure 46. Latin America Hospital Acquired Pneumonia Drugs Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Hospital Acquired Pneumonia Drugs Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Hospital Acquired Pneumonia Drugs Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. U.A.E Hospital Acquired Pneumonia Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Hospital Acquired Pneumonia Drugs by Type (2019-2030)

Figure 56. Global Revenue Market Share of Hospital Acquired Pneumonia Drugs by Type (2019-2030)

Figure 57. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Type (2019-2030)

Figure 58. Global Sales Market Share of Hospital Acquired Pneumonia Drugs by Application (2019-2030)

Figure 59. Global Revenue Market Share of Hospital Acquired Pneumonia Drugs by Application (2019-2030)

Figure 60. Global Hospital Acquired Pneumonia Drugs Price (USD/Kg) by Application (2019-2030)

Figure 61. Hospital Acquired Pneumonia Drugs Value Chain

Figure 62. Hospital Acquired Pneumonia Drugs Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-2316

Fri Mar 21 00:00:00 UTC 2025

$8000

Enterprise User

Add to Cart

Global Bilirubin Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

120 Pages

Type: Report

Code: QYRE-Auto-35U2436

Fri Mar 21 00:00:00 UTC 2025

$8000

Enterprise User

Add to Cart

Global Intracardiac Echocardiography Catheter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-7J13314

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global End Stage Renal Disease Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2F6212

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Hospital Acquired Pneumonia Drugs Market Research Report 2024

Published Date: January 2024

Report Code: QYRE-Auto-24P9747

Global Hospital Acquired Pneumonia Drugs Market Research Report 2024

FEATURED COMPANIES

Hospital Acquired Pneumonia Drugs Market Size

Hospital Acquired Pneumonia Drugs Market

Report Scope

Scope of Hospital Acquired Pneumonia Drugs Market Report

Chapter Outline

FAQ for this report

How fast is Hospital Acquired Pneumonia Drugs Market growing?

What is the Hospital Acquired Pneumonia Drugs Market size in 2030?

Who are the main players in the Hospital Acquired Pneumonia Drugs Market report?

What are the Application segmentation covered in the Hospital Acquired Pneumonia Drugs Market report?

What are the Type segmentation covered in the Hospital Acquired Pneumonia Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS

$8000

Enterprise User

$8000

Enterprise User

$5800

Enterprise User

$5800

Enterprise User